Abstracts by Dr. Beppino Giovanella, as of 5/2/2001

112. C. Verschraegen, W. Hu, J. Mendoza, Y. Du, A.P. Kudelka, R.S. Freedman, J.J. Kavanagh and B. Giovanella. Characterization of twenty-three Mullerian cell lines derived from primary ovarian cancers. Proc. AACR, Vol. 40, 1999.

111. L. Gong, B.C. Giovanella, and D.S-L. Chow. Sustained organ exposure to 9-nitro-camptothecin (9NC) lactone form by liposomal delivery. Proc. AACR, Vol. 40, 1999.

110. T.G. Burke, A.J Chavan, J.T. Strode, B. Giovanella, D. Yang, D.P. Curran, D. Bom, H. Josien, Y. Pommier, S. Zimmer, K.A. Fraley, and R. Perez-Soler. Development and evaluation of a liposomal formulation of highly lipophilic. Proc. AACR, Vol. 40, 1999.

109. Joachim G. Liehr, J. Mendoza, N. Harris, B.C. Giovanella, and T.G. Burke. Intrinsic anticancer activity of 9-nitrocamptothecin (9NC or RFS 2000) compared to 9-aminocamptothecin. Proc. AACR, Vol. 40, 1999.

108. A.S. Demir, C. Tanyeli, S. Zimmer, S. Kruszewski, A. Chavan, B. Giovanella, Y. Pommier, K.A. Fraley, and T.G. Burke. Synthetic design, physical and biological characterization of a novel water-soluble camptothecin analog containing a polyamine functionality at position 7. Proc. AACRVol. 40, 1999.

107. Z. Cao, B. Giovanella, J. Mendoza, A. Kozielski, J. Early, D. Vardeman, N. Harris, J. Liehr, and J. Stehlin. Structure-activity relationship of alkyl 9-nitrocamptothecin esters. Proc. AACR, Vol. 40, 1999.

106. Z. Cao, B. Giovanella, J. Mendoza, A. Kozielski, J. Early, D. Vardeman, N. Harris, J. Liehr, and J. Stehlin. 9-nitrocamptothecin: improved synthesis, in vitro and in vivo antitumor activity. Proc. AACR, Vol. 40, 1999.

105. Thomas G. Burke, Ashok J. Chavan, Beppino C. Giovanella, Stefan Kruszewski, A. Faley, A. Kimberly, T.D. Madden, M. Bally. Improved human blood stabilities and reduced clearance rates in mice for liposomal formulations of several clinically-relevant and experimental camptothecins. Proc. ASCO, Vol. 18, 1999.

104. Hagop Kantarjian, Jorge Cortes, Susan O’Brien, Claire F. Verschraegen, B. C. Giovanella, Z.Cao, and J.S. Stehlin. 9-Nitro-20(S)-Camptothecin (9-NC, RFS2000): An effective agent for treatment of chronic myelomonocytic leukemia (CMML) and Philadelphia Chromosome (Ph)-negative chronic myelogenous leukemia (CML). Proc. ASCO, Vol. 18, 1999.

103. L. Gong, B.C. Giovanella, and D.S-L. Chow. Improved lactone stability of 9-nitro-camptothecin in vitro and in vivo by liposomal formulation. Proc. AACR, Vol. 39, March, 1998.

102. Z. Cao, N. Harris, J. Mendoza, J. Early, A. Kozielski, D. Vardeman, and B. Giovanella. Alkyl esters of camptothecin: Synthesis, toxicity and antitumor activity. Proc. AACR, Vol. 39, March, 1998.

101. N.V. Koshkina, J.C. Waldrep, B.E. Gilbert, B.C. Giovanella, and V. Knight. Anticancer effect of liposomal 9-nitrocamptothecin aerosol delivery on human cancer xenograft models. Proc. ASCO, Vol. 39, March, 1998.

100. C. Verschraegen, Y. Du, J. Mendoza, A.P. Kudelka, R.S. Freedman, J.J. Kavanagh, and B. Giovanella. Characterization of mullerian cell line. Proc. ASCO, Vol. 39, March, 1998.

99. J.S. Stehlin, Jr., B.C. Giovanella, E.A. Natelson, D.R. Coil, P.D. de Ipolyi, K.M. Fehir, P.J. Wallace, A. Trojacek, J. Griswold, and D. Wolk. Clinical investigations of RFS 2000(9-Nitro-20(S)-Camptothecin-9NC in patients with advanced pancreatic carcinoma. Proc. ASCO, Vol. 17, 1998.

98. B.C. Giovanella, Z. Cao, D. Vardeman, J. Mendoza, T. Kozielski, C. Verschraegen, and J.S. Stehlin. Anti-tumor effects of RFS 2000 (9-Nitro-20(S)-Camptothecin-9NC). Proc. ASCO Meetings, Vol. 17, 1998.

97. A. Shenderova, S.P. Schwendeman, B. Giovanella, and T.G. Burke. Characterization of controlled release formulations of camptothecins composed of polylactide-co-glycolide (PLGA) microspheres. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

96. D.S-L. Chow, G. Chen, L. Gong, and B.C. Giovanella. Pharmacokinetics and in vivo antitumor activity of liposomal encapsulated camptothecin and its analog. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

95. D. Chatterjee, J. Wyche, B. Giovanella, and P. Pantazis. Lack of pro-caspase-3 activation in human leukemia U-937 cells resistant to etoposide. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

94. C. Verschraegen, J. Mendoza, S. Plaschke, B. Melichar, A. Loercher, R. Freedman, A. Kudelka, J., Kavanagh, J. Stehlin, and B. Giovanella. Rate of take of human ovarian cancer cells in vitro in tissue culture, and in vivo in nude mice. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

93. T.G. Burke, Y. Jiang, Y. Pommier, B. Giovanella, M.C. Wani, and M.E. Wall. Cellular pharmacology and preclinical evaluation of new lipophilic camptothecins modified in the 7- and 10-positions. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

92. J.S. Lundgren, G.K. Zoorob, B. Giovanella, Z. Cao, J. Liehr, T.L. Wang, and T.G. Burke. Camptothecin-20-ester pro-drugs display enhanced lipophillicity reduced protein binding, and improved human blood stabilities. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

91. E. Gupta, P. Sinko, A. Saleem, X-G. Li, F. Ahamed, R. Zamek, S. Goodin, D. Toppmeyer, E. Natelson, B. Giovanella, and E. Rubin. Oral multiple-dose camptothecin (CPT) pharmacokinetics: Evidence of inter-patient variability. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

90. C. Verschraegen, N. Harris, M. Steger, J. Kavanagh, A. Kudelka, and B.C. Giovanella. Pharmacology study of multiple oral doses of 9-Nitrocamptothecin (9NC). 88th Annual AACR Meeting; San Diego, CA; April, 1997.

89. A. Shenderova, B. Giovanella, C.B. Munshi, D. Warner, and T.G. Burke. 9-Aminocamptothecin and 9-nitrocamptothecin exhibit markedly different stabilities in human versus animal blood. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

88. P.S. Cole, G.K. Zoorob, J.L. Lundgren, B. Giovanella, M.C. Wani, M.E. Wall, and T.G. Burke. Membrane interactions, protein binding, and anticancer activities of a series of camptothecins modified at the 9-position. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

87. Z. Cao, P. Pantazis, B. Giovanella, J. Mendoza, A. Kozielski, and D. Vardeman. An alkenyl ester of camptothecin and its epoxy derivative: Synthesis, in vitro and in vivo anticancer activity. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

86. B. Giovanella, P. Pantazis, Z. Cao, D. Vardeman, J. Mendoza, and J. Stehlin. Anticancer activity of stabilized camptothecins in vitro and in vivo. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

85. D. Chatterjee, J. Wyche, B. Giovanella, and P. Pantazis. Lack of pro-caspase-3 activation in human leukemia U-937 cells resistant to etoposide. 88th Annual AACR Meeting; San Diego, CA; April, 1997.

84. P. Pantazis, N. Harris, H. Hinz and B. Giovanella. Conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human, dog, and mouse cells in vivo and in vitro. Proc. Am. Assoc. Cancer Res. 36;447(2667); 1995.

83. M. Potmesil, L. Liebes, J. Drygas, S. Sekiya, L. Morse, A.J. Kozielski, M.E. Wall, M.C. Wani, J.S. Stehlin and B.C. Giovanella. Pharmacodynamics/pharmacokinetics of intragastric (IG) camptothecin analogs in a human cancer xenograft model. Proc. Am. Assoc. Cancer Res. 36;445(2652); 1995.

82. P. Pantazis, J. Mendoza, J. Early, A. DeJesus, and B. Giovanella. Sequential treatments of leukemia cells with 9-nitrocamptothecin and other anticancer drugs: Overcoming resistance. Proc. Am. Assoc. Cancer Res. 36;444(2646); 1995.

81. B.C. Giovanella, D.M.Vardeman, A.J. Kozielski, J.S. Stehlin, and M. Potmesil. Enhanced antitumor effectiveness of camptothecin (CPT) and derivatives administered by continuous infusion through scheduling and combination with DNA damaging agents. Proc. Am. Assoc. Cancer Res. 36;391(2328); 1995.

80. B. Giovanella, M. Potmesil, M.E. Wal, J.S. Stehlin, H. Hinz, D. Vardeman, and J. Mendoza. Treatment of human cancer xenografts with camptothecin analogues in combination with cytoxan or x-irradiation. Proc. Am. Assoc. Cancer Res. 35;454(2711); 1994.

79. B.C. Giovanella, J.S. Stehlin, H.R. Hinz, D. Vardeman, J.T. Mendoza and M. Potmesil. Studies of time/dose intensity in treatment of human cancer xenografts with camptothecin analogues. Proc. Am. Assoc. Cancer Res. 35;455(2713); 1994.

78. P. Pantazis, J. Early, J. Mendoza, A. DeJesus, M. Shaw and B. Giovanella. Cell-cycle inhibitors modulate efficiency of 9-nitro-camptothecin in the treatment of human malignant cells. Proc. Am. Assoc. Cancer Res. 35;455(2712); 1994.

77. B.C. Giovanella, M.E. Wall, M.C. Wani, R. Silber, J.S. Stehlin, H. Hochster and M. Potmesil. Efficacy of camptothecin [NSC 94600],9-aminocamptothecin [NSC 606174] in the human cancer xenograft model. Proc. Am. Assoc. Cancer Res. 33;507(2583); 1992.

76. P. Pantazis, E. Rubin, D. Kufe, B. Giovanella and E. Natelson. Studies of human leukemia cells with 9-nitro-camptothecin. Proc. Am. Assoc. Cancer Res. 34;295(1753); 1993.

75. B.C. Giovanella, M.E. Wall, M.C. Wani, J.S. Stehlin, H.R. Hinz, D. Vardeman, J. T. Mendoza , A.J. Kozielski and M. Potmesil. 10,11-Methylenedioxy camptothecins: Studies in human cancer xenografts. Proc. Am. Assoc. Cancer Res. 34;327(1947); 1993.

Top of Page

74. S.S. Daoud, M.I. Fetouh and B.C. Giovanella. Multilamelar liposomes as a delivery system for camptothecin (NSC 94600) and 9-aminocamptothecin (NSC 603071). Proc. Am. Assoc. Cancer Res. 34;367(2188);1993.

73. P. Pantazis, J. Mendoza, J. Early, A. Kozielski and B.C. Giovanella. Camptothecins induce expression of specific mRNAs in human leukemia cells in vitro and inhibit growth of the leukemia cells as solid tumors in nude mice. Proc. Am. Assoc. Cancer Res. 33;507(3033);1992.

72. P. Pantazis, J. Mendoza, J. Early, A. Kozielski and B.C. Giovanella. Camptothecin-induced responses of human ovarian and breast carcinoma cells in vitro that correlates with their tumorigenic ability in vivo. Proc. Am. Assoc. Cancer Res. 33;507(3031); 1992.

71. M. Potmesil, H.R. Hinz, A. Marcee, D. Vardeman, J.S. Stehlin, M.E. Wall, M.C. Wani, R. Silber and B.C. Giovanella. Growth inhibition of human cancer metastases in the xenograft model by camptothecin (NSC 94600, 9-amino-[NSC 603071] and 9-nitrocamptothecin. Proc. Am. Assoc. Cancer Res. 33:507(2582); 1992.

70. P.L. Smith, J.G. Liehr, S. Jacob, A.E. Ahmed, H.R. Hinz, J. Mendoza, A. Kozielski, J.S. Stehlin and B.C. Giovanella. Pharmacokinetics of tritium-labeled camptothecin in nude mice. Proc. Am. Assoc. Cancer Res. 33;(507 2579); 1992.

69. P. Pantazis, H.R. Hinz, J. Tschen, J.S. Stehlin and B.C. Giovanella. Specific responses of human melanoma cells to treatment with camptothecin-derivatives in vitro. Proc. Am. Assoc. Cancer Res. 32; 383 (2278); 1991.

68. M. Potmesil, M.E. Wall, M.C. Wani, R. Silber, J.S. Stehlin and B.C. Giovanella.

67. B.C. Giovanella, J.S. Stehlin, D. Vardeman, R. Silber, and M. Potmesil. DNA topoisomerase I-targeted treatment of liver and brain-stem metastases in xenografts. Proc. Am. Assoc. Cancer Res. 32; 337(1999); 1991.

66. S.M. Kharbanda, E. Rubin, H.R. Hinz, B.C. Giovanella, P. Pantazis, and D. Kufe . Camptothecin derivatives induce expression of the c-jun proto-oncogene in human myeloid leukemia cells. Proc. Am. Assoc. Cancer Res. 32;336(1995); 1991.

65. F.Z. Bischoff, L.C. Strong, B.C. Giovanella, and M.A. Tainsky. Spontaneous Immortalization due to loss of heterozygosity at P53 in fibroblasts from Li-Fraumeni familial cancer patients. Proc. Am. Assoc. Cancer Res. 32:306(1817); 1991.

64. P. Pantazis, J. Mendoza, J. Early, A. De Jesus, and B. Giovanella, B. Sequential treatments of leukemia cells with 9-nitrocamptothecin and other anticancer drugs: Overcoming resistance. 86th Annual AACR Meeting; Toronto, Ontario, Canada, March 1995.

63. P. Pantazis, N. Harris, H. Hinz, and B. Giovanella. Conversion of 9-nitrocamptothecin to

62. P. Pantazis, J. Early, J., Mendoza, A. DeJesus, M. Shaw, and B. Giovanella. Cell-cycle inhibitors modulate efficiency of 9-nitro-camptothecin in the treatment of human malignant cells. 85th Annual AACR Meeting; San Francisco, CA; April 1994.

61. P. Pantazis, E. Rubin, D. Kufe, B. Giovanella, and E. Natelson. Studies of human leukemia cells with 9-nitro-camptothecin. 84th Annual AACR Meeting; Orlando, FL; May 1993.

60. P. Pantazis, E. Rubin, A. Bharti, D. Kufe, and B.C.Giovanella. Induction of apoptosis in camptothecin-treated malignant cells and in camptothecin-resistant cells. Conference on "Cell Death in Cancer and Development"; Chatham, MA; October 1993.

59. P.T. Reissmann, R. Takahashi, B. Giovanella, J-C. Ramos, M.F. Press, and D.J. Slamon. RAB gene inactivation in human breast cancer specimens and nude mouse xenografts. Proc. Am. Assoc. Cancer Res. 33;381(2273); 1992.

58. S. Sen, B.C. Giovanella, P. Sen, C. Hirsch-Ginsberg, R.B. Arlinghaus, J.M. Trujillo, E. J. Freireich, and S.A. Stass. Deletion of chromosome 1q accompanying loss of tumorigenicpotential in CML blast crisis K562 cells with functional P210bcr-abTTyrosine Kinase. Proc. Am. Assoc. Cancer Res. 33;129(776); 1992.

57. E.A. Natelson, J.S. Stehlin, K.M. Fehir, H.R. Hinz, B.C. Giovanella, and Pantazis, P. Camptotheca acuminata -- Not just another pretty tree. Results of Phase I cancer studies with 20(S)- camptothecin. VI International Congress on Traditional and Folk Medicine; Kingsville, TX; November 1992.

56. P. Pantazis, J. Mendoza, J. Early, A. Kozielski, and B.C. Giovanella. Camptothecin-induced responses of human ovarian and breast carcinoma cells in vitro that correlate with their tumorigenic ability in vivo. 83rd Annual AACR Meeting; San Diego, CA; May 1992.

55. P. Pantazis, J. Mendoza, J. Early, A. Kozielski, and B.C. Giovanella. Camptothecins induce expression of specific mRNAs in human leukemia cells in vitro and inhibit growth of the leukemia cells as solid tumors in nude mice. 83rd AACR Meeting; San Diego, CA; May 1992.

54. 9-Amino [NSC 629971, 9-AC] and 10,11-methylenedioxy [NSC 606174, 10,11-MDC] camptothecins in the treatment of human cancer xenografts. Proc. Am. Assoc. Cancer Res. 32;337(2003); 1991.

53. P. Pantazis, H.R. Hinz, J. Tschen, J.S. Stehlin, and B.C. Giovanella. Specific responses of human melanoma cells to treatment with camptothecin derivatives in vivo. 82nd Annual AACR Meeting; Houston, TX; May 1991.

52. S.M Kharbanda, E. Rubin, H.R. Hinz, B.C. Giovanella, P. Pantazis, and D. Kufe. Camptothecin derivatives induce expression of the c-jun proto-oncogene in human myeloid leukemia cells. 82nd Annual AACR Meeting; Houston, TX; May 1991.

51. M.A. Tainsky, F. Zamaniyan, S.O. Yim, S. Pathak, B.C. Giovanella and L.C. Strong. Normal Fibroblasts Derived from Patients with Li-Fraumen: Cancer Syndrome Spontaneously Transform In Vitro. Proc. Am. Assoc. Cancer Res. 30: 315 (1250), 1989.

50. B.C. Giovanella, D.M. Vardeman, L.J. Williams, D.J. Taylor, J.S. Stehlin, A. Ullrich, H.E. Gary and D.J. Slamon. Poor Prognosis of Breast Cancer Patients Whose Tumor Took in Nude Mice. Correlation with Amplification and Overexpression of the HER-2/neu Oncogene. Proc. Am. Assoc. Cancer Res. 30: 60 (235), 1989.

Top of Page

49. B.C. Giovanella, A. Ullrich, D.J. Slamon and J.S. Stehlin. Correlation of Poor Prognosis in Breast Cancer with Growth in Nude Mice and Amplification/Overexpression of the HER-2/neu Oncogene. 18th UCLA Annual Symposium, J. Cell. Biochem. Suppl. 13B 104 (E209), 1989.

48. B.C. Giovanella, C.F. Verschraegen, L.J. Williams and J.S. Stehlin. Pathology of Early Experimental Metastases of Human Melanomas in Nude Mice. F.A.S.E.B. Proc. - F.A.S.E.B. J. 2: A6461, 1988.

47. D. Ranney, P. Antich, J. Cohen, W. Erdman, P. Kulkarni and B. Giovanella. Submillimiter Monitoring of Tumor-Treatment Response by Contrast-Enhanced Magnetic Resonance Imaging (MRI): Implication for Tumor Access of Antibodies; Lymphokines and Macromolecular Drugs. Proc. Am. Assoc. Cancer Res. 29: 496 (1967), 1988.

46. B.C. Giovanella, D.M. Vardeman and J.S. Stehlin. Further Studies on Rapid Screening of Anticancer Agents by 111In Labeled Human Cancer Cells Inoculated in Nude Mice. Proc. Am. Assoc. Cancer Res. 29: 493 (1961), 1988.

45. P.P. Antich, B.C. Giovanella, R.P. Mason, B.L. Nunnally, D.F. Ranney and E.P. Frenkel. Metabolic Changes During In Vivo Human Tumor Xenograft Diphtheria Toxin Induced Cell Kill as Measured by 32P Magnetic Resonance spectroscopy. Proc. Am. Assoc. Cancer Res. 29: 76 (301), 1988.

44. C.F. Verschraegen, B.C. Giovanella, T. Kozielski, J.T. Mendoza and J.S. Stehlin. Increased Sensitivity to Cyclophosphamide (Cy) of Artificial Metastases of a Human Melanoma Clone in Nude Mice. Proc. Am. Assoc. Cancer Res. 29: 61 (244), 1988.

43. B.C. Giovanella, E.A. Natelson, T. Kozielski and J.S. Stehlin, Jr. Allogenic Bone Marrow Transplantation in Nude Mice After Lethal Doses of Cyclophosphamide. Proc. Am. Assoc. Cancer Res. 28: 431 (1707), 1987.

42. B.C. Giovanella, C.F. Verschraegen, T. Kozielski and J.S. Stehlin, Jr. Distribution and Fate of 111In Labelled Human Melanoma Cells After Intracardiac and Intravenous Injection in Nude Mice. Proc. Am. Assoc. Cancer Res. 28: 75 (299), 1987.

41. C.F. Verschraegen, B. C. Giovanella, J.T. Mendoza and J.S. Stehlin, Jr. Metastatic Spread of Human Melanoma Clones Inoculated in the Arterial and Venous Circulation of Nude Mice. Proc. Am. Assoc. Cancer Res. 28: 75 (298), 1987.

40. A. Lockshin, B.C. Giovanella, D.J. Taylor and J.S. Stehlin. Quantitation of Human Tumor Cell Kill in Nude Mice After Administration of Anticancer Drugs. Proc. Am. Assoc. Cancer Res. 27: 382 (1515), 1986.

39. C. Greco, A. Candiloro, A. Caputo, C.M. Carapello, B. Giovanella, A. Riccio, B. Silvistrini and G. Zupi. Characterization and Chemosensitivity of Two Human Glioma-Derived Cell Lines. Proc. Am. Assoc. Cancer Res. 27: 26 (98), 1986.

38. A. Lockshin, B.C. Giovanella, T. Kozielski, J.T. Mendoza, J.S. Stehlin, Jr. Studies with 111Indium-Labeled Human Tumor Cells. Proc. Am. Assoc. Cancer Res. 26: 363 (1434), 1985.

37. A. Lockshin, B.C. Giovanella, C. Quian, J.T. Mendoza, D.M. Vardeman, J.S. Stehlin, Jr. A Rapid Method to Determine Cytotoxicity in Radioactive Prelabeling of Human Tumor Cells Inoculated in Nude Mice. Proc. Am. Assoc. Cancer Res. 25: 1325 (1293), 1984.

36. A. Lockshin, B.C. Giovanella, D.M. Vardeman, C. Quian, J.T. Mendoza and J.S. Stehlin. Activity of Drugs as Determined by Loss of Radioactivity from Nude Mice Inoculated with 125I-Iododeoxyuridine(125IUDR)-Labelled Human Tumor Cells. Proc. Am. Assoc. Can. Res. 24: 307 (1213), 1983.

35. A. Lockshin, B.C. Giovanella, J.T. Mendoza and J.S. Stehlin. Biochemical and Cytotoxic Effects of Thymidine (TdR) and 3-Deazauridine (DAUR) on Human Melanoma Cells. Proc. Am. Assoc. Cancer Res. 23: 4 (16); 1982.

34. R.D. Rossen, D.B. Dubois, D.A. Beck, M. Crane, J. Abramowitz, C.O. Felice, A.C. Morgan, R. Cailleau, B. Giovanella, E.R. Blumenschein and E.H. Hersh. Soluble Immune Complexes (IC) and Antibodies (Ab) to Cultured Tumor Cells in Cancer Patients's Sera. Proc. 13th Int. Cancer Congress, 1982, No. 2487, p. 436.

33. B.C. Giovanella, J.S. Stehlin, R.C. Shepard and L.J. Williams. Correlation Between Response to Chemotherapy of Human Tumors in Patients and in Nude Mice. Proc. 13th Int. Cancer Congress, 1982, No. 102, p. 21.

32. L.P. Rutzky, B. Giovanella, M.J. Siciliano, H.A. Fritsche and B.D. Kahan. Clonal Heterogeneity of a Human Colon Adenocarcinoma Line, LS 174T. Proc. 13th Int. Cancer Congress, 1982, No. 1068, p. 189.

31. B.C. Giovanella, R.C. Shepard and J.S. Stehlin. Correlation Between Response to Chemotherapy of Human Tumors in Patients and in Nude Mice. In: Current Chemotherapy and Immunotherapy, Proc. 12th Int. Congress of Chemotherapy, 1981, Vol. II, p. 1234, 1982.

30. K.J. McCormick, R.C. Shepard and J.S. Stehlin. Cell Mediated Immune Parameters in Three Strains of Nude Mice Which Differ in Susceptibility to Heterografts of Human Cells. Fed. Proc. 39: 1146, 1980.

29. B.C. Giovanella, K.J. McCormick, J.S. Stehlin, J.M. Venditti and B.J. Abbott. Effects of Caloric Restriction on the Growth of Human Xenografts to Nude Mice. Proc. Am. Assoc. Cancer Res. 21: 257, 1980.

28. B.C. Giovanella, R.C. Shepard, J.S. Stehlin, J.M. Venditti and B.J. Abbott. Effects of Caloric Restriction on the Growth of Human Xenografts to Nude Mice. Proc. Am. Assoc. Cancer Res. 21: 257, 1980.

27. K.J. McCormick, J.S. Stehlin, B.C. Giovanella, P.D. de Ipolyi and M.A. Shalett. Immunological Parameters in Phase I Studies of Patients Continuously Infused with Thymidine. Proc. Am. Assoc. Cancer Res. 21: 176, 1980.

26. K.J. McCormick, J.S. Stehlin, P.D. de Ipolyi, B.C. Giovanella, J.V. Ruzich and R.F. Anderson. Monocyte Function During Systemic Hyperthermia Induced by Corynebacterium Parvum. Am. Assoc. Cancer Res. 20: 155, 1979.

25. B.C. Giovanella, S.O. Yim and J.S. Stehlin. Cell Subpopulations of a Cultured Human Tumor Differing by Rate of Growth In Vivo as Heterotransplants in Nude Mice and by Modal Chromosome Numbers. Proc. Tissue Culture Assoc., 1979, p. 197.

Top of Page

24. D.S. Zaharko, B.J. Bolten, B.C. Giovanella and J.S. Stehlin. Thymidine and Thymidine Measurements in Biological fluids, Mouse, Monkey and Man. Proc. Am. Assoc. Cancer Res. 20: 62, 1979.

23. S.S. Lee, B.C. Giovanella, J.S. Stehlin and J.C. Brunn. Further Studies on the Long-Term Effects of High Dose Thymidine Infusion (TdR) on Human Tumors Heterotransplanted in Nude Mice. Proc. Am. Assoc. Cancer Res. 20: 234, 1979.

22. A.C. Morgan, R.D. Rossen, J.J. Twomey, B.C. Giovanella and E.M. Hersh. Immune Complexes Containing Tumor Cytotoxins and Antiglobulin May Be Found in Both Normal Donor Cancer Patients' Sera. Fed. Proc. 38: 1177, 1979.

21. K.J. McCormick, B.C. Giovanella, J.S. Stehlin, P.D. de Ipolyi and W.R. Parsons. Cellular Cytotoxicity Against Autochthonous Human Melanoma Cells. Fed. Proc. 38: 1105, 1979.

20. B.C. Giovanella, J.J. Williams, S.S. Lee and J.S. Stehlin. Morphological Effects of High Concentrations of Thymidine on Normal and Neoplastic Dividing Cells In Vitro and In Vivo. Fed. Proc. 38: 918, 1979.

19. K.J. McCormick, J.S. Stehlin, B.C. Giovanella, P.D. de Ipolyi, M.J. Ware, D.C. Day and R.F. Anderson. Specific and Non-Specific Lymphocyte Responses to Mitogens During Systemic Hyperthermia for Malignant Melanoma. Proc. Am. Assoc. Can. Res. 19: 103, 1978.

18. S.S. Lee, B.C. Giovanella, J.S. Stehlin and J.C. Brunn. Regression of Established Human Tumors in Nude Mice Induced by Continuous Infusion of Thymidine (TdR). Proc. Am. Assoc. Cancer Res. 19: 103, 1978.

17. B.C. Giovanella, J.S. Stehlin and R.C. Shepard. Experimental Chemotherapy of Human Malignant Tumors Transplanted Subcutaneously and Under the Kidney Capsule of Nude Mice. Fed. Proc. 37: 499, 1978.

16. K.J. McCormick, J.S. Stehlin, B.C. Giovanella, P.D. de Ipolyi, M.J. Ware, D.C. Day and R.F. Anderson. Specific and Non-Specific Lymphocyte Responses to Mitogens During Systemic Hyperthermia for Malignant Melanoma. Proc. Am. Assoc. Cancer Res. 19: 103, 1978.

15. B.C. Giovanella, J.S. Stehlin, R.C. Shepard and A. Goldin. Experimental Chemotherapy of Human Malignant Tumors Serially Heterotransplanted in Nude Mice. Proc. Am. Assoc. Can. Res. 18: 27, 1977.

14. B.C. Giovanella, J.S. Stehlin, S.S. Lee, R. Shepard and L.J. Williams. Heterotransplantation of Human Breast Carcinomas in "Nude" Thymus Deficient Mice. Proc. Am. Assoc. Can. Res. 17: 124, 1976.

13. B.C. Giovanella, J.S. Stehlin, L.J. Williams and G. Klein. Influence of the Host's Sex on the Pattern of Tumor Induction by Injection of Polyoma Virus in "Nude" Thymus Deficient Mice. Proc. Am. Assoc. Cancer Res. 16: 141, 1975.

12. B.C. Giovanella and J.S. Stehlin. Influence of the Host's Sex on the Growth of Human Tumors Heterotransplanted in "Nude" Thymusless Mice. Proc. Am. Assoc. Cancer Res. 15: 23, 1974.

11. J.S. Stehlin, B.C. Giovanella, S.S. Lee and L.J. Williams. Patterns of Growth and Metastatic Spread of Human Malignant Tumors (Epitheliomas, Sarcomas and Melanomas) Transplanted in "Nude" Thymusless Mice. Proc. Am. Assoc. Cancer Res. 15: 24, 1974.

10. B.C. Giovanella, A.C. Morgan, J.S. Stehlin, L.W. Williams, Jr. and D.M. Mumford. Development of Invasive Tumors in "Nude" Thymusless Mice Injected with Human Cells Cultured from Burkitt Lymphomas. Proc. Am. Assoc. Cancer Res. 14: 20, 1973.

9. B.C. Giovanella, D.M. Mumford, C.S. Santamaria and J.S. Stehlin. Cytotoxic Effect of Autologous Lymphocytes and Plasma on Cultured Human Tumors. Proc. Am. Assoc. Cancer Res. 13: 77, 1972.

8. B.C. Giovanella, C.S. Gist, C.A. Morgan and J.S. Stehlin. Effects of Elevated Temperatures and Drugs on Neoplastic Cells of Human and Murine Origin in Tissue Culture. Proc. Am. Assoc. Cancer Res. 12: 101, 1971.

7. B.C. Giovanella, W.A. Lohman and C. Heidelberger. Synergistic Lethal Effect of Elevated Temperature and L-Erythro-dihydroxybutyraldehyde on L1210 Leukemic Cells. Tenth Int. Cancer Cong. 573: 1970.

6. B.C. Giovanella, R. Mosti and C. Heidelberger. Further Studies on the Lethal Effects of Heat on Tumor Cells. Proc. Am. Assoc. Cancer Res. 10: 29, 1969.

5. B.C. Giovanella and C. Heidelberger. Biochemical and Biological Effects of Heat on Normal and Neoplastic Cells. Proc. Am. Assoc. Cancer Res. 24, 1968.

4. B.C. Giovanella and C. Heidelberger. Studies on the Role of the Hair Follicle in Epidermal Carcinogenesis. Proc. Am. Assoc. Cancer Res. 8: 21, 1967.

3. B.C. Giovanella, M.R. Roller and R.H. Christenson. Biological Characteristics of Cells from Primary Hydrocarbon-Induced Skin Carcinomas. Ninth International Cancer Congress 36: 1966.

2. B.C. Giovanella, R.J. Palzer and C. Heidelberger. A New Method of Cell Fractionation. Proc. Am. Assoc. Cancer Res. 7: 24, 1966.

1. B.C. Giovanella and C. Heidelberger. Autoradiography and Enzymatic Dissection of Mouse Skin Following Application of Tritiated Polycyclic Hydrocarbons. Proc. Am. Assoc. Cancer Res. 4: 23, 1963.